Analysis of coverage of medical health plans related to COVID-19 detection tests in Brazil
DOI:
https://doi.org/10.33448/rsd-v10i8.17041Keywords:
Coronavirus infections; Supplementary health; Health services.Abstract
With the declaration of the new Coronavirus pandemic (COVID-19) by the World Health Organization (WHO), onMarch 11, 2020, the escalation by research on possible strategies for its confrontation has reached a new level. The objective of this study was to evaluate the coverage of health insurance companies in relation to COVID-19 tests determined by the National Supplementary Health Agency (ANS) and to analyze the number of COVID-19 tests performed in Brazil. This is a documentary, ecological study, which was carried out from March 2020 to March 2021. The data released by the National Supplementary Health Agency was verified in relation to the tests included in the List of Procedures and Events in Health of ANS. In the state health departments, the number of tests performed daily in Brazil was analyzed. During this period 07 tests were implemented by ANS: SARS-CoV-2 (CORONAVIRUS COVID-19) - RT search - PCR (with usage guidelines), D-Dimer (dosage), Procalcitonin (dosage), Research tests rapid for Influenza A and B, and real-time PCR for Influenza A and B viruses in addition to the Quick Search tests for Respiratory Syncytial Virus and real-time PCR for Respiratory Syncytial Virus. The Southeast region carried out the largest number of tests in Brazil, with almost 50% of the total, followed by the Northeast region, which tested approximately 25% of the inhabitants. The types of tests determined by the ANS are in accordance with the recommendations of the Ministry of Health of Brazil, however, it is concluded that some health plan operators are not following the determination of the ANS in relation to the coverage of these tests, negatively influencing the number of tests carried out in the country.
References
Agência Nacional de Saúde Suplementar (2021). Metodologia de cálculo. http://www.ans.gov.br/planos-de-saude-e-operadoras/espaco-doconsumidor/reajuste-variacao-de-mensalidade/reajuste-anual-de-planos-individuais-familiares/metodologia-de-calculo
Agência Nacional de Saúde Suplementar (2020a). ANS inclui exame para detecção de Coronavírus no rol de procedimentos obrigatórios. http://www.ans.gov.br/aans/noticias-ans/consumidor/5405-ans-inclui-exame-para-deteccao-de-coronavirus-no-rol-de-procedimentosobrigatorios
Agência Nacional de Saúde Suplementar (2020b). ANS inclui mais seis exames no rol para auxiliar no diagnóstico e tratamento do novo Coronavírus. http://www.ans.gov.br/aans/noticias-ans/coronavirus-covid-19/coronavirus-todas-as-noticias/5546-ans-inclui-mais-seis-exames-norol-de-coberturas-obrigatorias-para-auxiliar-na-deteccao-do-novo-coronavirus
ANS: planos de saúde devem disponibilizar exames para detectar coronavírus (2020). https://www.migalhas.com.br/quentes/321653/ans--planosde-saude-devem-disponibilizar-exames-para-detectar-coronavirus
Beeching, N. J., Fletcher, T. E., & Beadsworth, M. (2020). Covid-19: testing times. BMJ, 369, m1403.
Brasil. Ministério da Saúde (2020a) Laboratórios públicos ampliam em 869% capacidade de testagem para Covid-19 no Brasil. https://antigo.saude.gov.br/noticias/agencia-saude/47151-laboratorios-publicos-ampliam-em-869-capacidade-de-testagem-para-covid-19-nobrasil
Brasil. Ministério da Saúde (2020b). Centro de informações estratégicas em vigilância em saúde – CIEVS http://bvsms.saude.gov.br/bvs/publicacoes/centro_informacoes_estrategicas_vigilancia_saude.pdf
Brasil. Ministério da Saúde (2020c). Emergência de saúde pública de importância nacional pela doença pelo Coronavírus 2019: vigilância integrada de síndromes respiratórias agudas doença pelo Coronavírus 2019, influenza e outros vírus respiratórios.
Forato, F. (2020). COVID-19 no BR: quase metade dos testes foram feitos em 5 laboratórios privados. https://canaltech.com.br/saude/covid-19no-br-quase-metade-dos-testes-foram-feitos-em-5-laboratorios-privados-165637/
Fundação Oswaldo Cruz (2020). Organização Mundial da Saúde quer testes e isolamento de casos suspeitos para conter Covid-19. https://www.canalsaude.fiocruz.br/noticias/noticiaAberta/organizacao-mundial-da-saude-quer-testes-e-isolamento-de-casos-suspeitos-paraconter-covid-1916032020#:~:text=A%20Organiza%C3%A7%C3%A3o%20Mundial%20da%20Sa%C3%BAde,daqueles%20com%20suspeita%20de%20infe c%C3%A7%C3%A3o
Guaracho, R. F. (2020). Planos de saúde não podem recusar cobertura dos testes do coronavírus. https://www.jornaldocomercio.com/_conteudo/e speciais/ orn al_da_lei /2020/03/731909-planos-de-saude-nao-podem-recusar-cobertura-dostestes-do-coronavirus.html
Hasell, J., Ortiz-Ospina, E., Mathieu, E., Ritchie, H., Beltekian, D.M.B., & Roser, M. (2020). To understand the global pandemic, we need globas testing - the Our World in Data COVID-19 Testing dataset. University of Oxford.
Heymann, D. L., Shindo, N., & WHO Scientific and Technical Advisory Group for Infectious Hazards (2020). COVID-19: what is next for public health? Lancet, 395(10224), 542–545.
Huang, L., Zhang, X., Zhang, X., Wei, Z., Zhang, L., Xu, J., Liang, P., Xu, Y., Zhang, C., & Xu, A. (2020). Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study. The Journal of Infection, 80(6), e1–e13.
Kang, D., Choi, H., Kim, J. H., & Choi, J. (2020). Spatial epidemic dynamics of the COVID-19 outbreak in China. International Journal of Infectious Diseases, 94, 96–102.
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K., Lau, E., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, R., Liu, H., Luo, Y., Liu, Y., Shao, G., Li, H., Tao, Z., Yang, Y., Deng, Z., Liu, B., Ma, Z., Zhang, Y., Shi, G., Lam, T.T.Y., Wu, J.T., Gao, G.F., Cowling, B.J., Yang, B., Leung, G.M., & Feng, Z. (2020).
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. The New England Journal of Medicine, 382(13), 1199– 1207.
Ng, Y., Li, Z., Chua, Y. X., Liang, W., Zhao, Z., Er, B., Pung, R., Chiew, C. J., Lye, D. C., Heng, D., & Lee, V J . (2020). Evaluation of the effectiveness of surveillance and containment measures for the first 100 patients with COVID-19 in Singapore — january 2–february 29, 2020. Morbidity and Mortality Weekly Report, 69(11), 307-311.
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. UFSM. https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1.
Peto, J. (2020). Covid-19 mass testing facilities could end the epidemic rapidly. BMJ, 368, m1163.
Reusken, C., Broberg, E. K., Haagmans, B., Meijer, A., Corman, V. M., Papa, A., Charrel, R., Drosten, C., Koopmans, M., Leitmeyer, K., & On Behalf Of Evd-LabNet And Erli-Net (2020). Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Euro Surveillance, 25(6), 2000082.
Rong, X. M., Yang, L., Chu, H. D., & Fan, M. (2020). Effect of delay in diagnosis on transmission of COVID-19. Mathematical Biosciences and Engineering, 17(3), 2725–2740.
Stephanou, G. (2021). Painel COVID-19: estatísticas do coronavírus em tempo real. Disponível em http://www.giscard.com.br/coronavirus/indicetestes-realizados-covid19-brasil.php
Teixeira, M. G., Costa, M. C. N., Carmo, E. H., Oliveira, W. K., & Penna, G. O. (2018). Health surveillance at the SUS: Development, effects and perspectives. Ciência & Saúde Coletiva, 23(6), 1811-1818.
Universidade do Estado do Rio de Janeiro (2020). Estudo mostra eficiência do isolamento social contra o novo coronavírus. https://www.uerj.br/noticia/11078/
World Health Organization (2020). Rolling updates on coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novelcoronavirus-2019/events-as-they-happen
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Clea Adas Saliba Garbin; Julio Martinez Alves Oliveira; Tânia Adas Saliba; Gabriel Zopolatto Turci Dias; Artênio José Isper Garbin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
